Certuity LLC Grows Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Certuity LLC raised its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 17.1% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 808 shares of the medical research company’s stock after purchasing an additional 118 shares during the period. Certuity LLC’s holdings in Thermo Fisher Scientific were worth $429,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. Raleigh Capital Management Inc. boosted its stake in Thermo Fisher Scientific by 49.1% during the 3rd quarter. Raleigh Capital Management Inc. now owns 82 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 27 shares during the period. Cedar Mountain Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 107.0% in the 4th quarter. Cedar Mountain Advisors LLC now owns 89 shares of the medical research company’s stock worth $47,000 after purchasing an additional 46 shares in the last quarter. Financial Connections Group Inc. bought a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth approximately $53,000. Operose Advisors LLC raised its holdings in shares of Thermo Fisher Scientific by 250.0% in the 3rd quarter. Operose Advisors LLC now owns 105 shares of the medical research company’s stock worth $53,000 after purchasing an additional 75 shares in the last quarter. Finally, Valley National Advisers Inc. raised its holdings in shares of Thermo Fisher Scientific by 40.5% in the 3rd quarter. Valley National Advisers Inc. now owns 111 shares of the medical research company’s stock worth $56,000 after purchasing an additional 32 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research firms recently commented on TMO. Barclays boosted their target price on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday, April 25th. Sanford C. Bernstein restated a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. HSBC boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird cut their price target on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a report on Thursday, April 25th. Finally, The Goldman Sachs Group boosted their price target on shares of Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Five research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $607.35.

Thermo Fisher Scientific Stock Performance

TMO stock opened at $568.74 on Wednesday. The company has a quick ratio of 1.33, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. The company has a market capitalization of $217.09 billion, a price-to-earnings ratio of 36.48, a P/E/G ratio of 2.40 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The firm has a 50 day moving average of $574.58 and a two-hundred day moving average of $531.67.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The company had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.59 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date of this dividend was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now directly owns 1,207 shares in the company, valued at approximately $660,192.79. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at $7,250,362. The disclosure for this sale can be found here. In the last three months, insiders sold 52,277 shares of company stock valued at $29,649,264. Company insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.